關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Experience」新聞搜尋結果, 共 19081 篇 ,以下為 13777 - 13800 篇 訂閱此列表,掌握最新動態
HKBU unveils treatment potential of herbal extract compound isoliquiritigenin for pancreatic cancer

HONG KONG SAR - Media OutReach - 7 August 2023 - A research led by scientists of Hong Kong Baptist University (HKBU) found that isoliquiritigenin (ISL), a flavonoid isolated from the Chinese herbal medicine licorice, can inhibit pancreatic cancer progression. It may also enhance the efficacy of conventional chemotherapeutic drugs in treating pancreatic cancer. It is the first time that a research group reported the anticancer potential of ISL in treating pancreatic cancer. A research team led by Dr Joshua Ko Ka-shun, Associate Professor, Teaching and Research Division of the School of Chinese Medicine at HKBU, found that isoliquiritigenin, a herbal extract compound of the Chinese herbal medicine licorice, can inhibit pancreatic cancer progression. The research findings have been published in the international academic journal Phytomedicine and recently presented in the Annual Congress of the European Association for Cancer Research 2023 in Torino, Italy. Pancreatic cancer as the "silent killer" Pancreatic cancer is often called the "silent killer" as most patients experience little or no symptoms until it has advanced and spread. According to the Global Cancer Statistics 2020 released by the International Agency for Research on Cancer, the mortality-to-incidence ratio of pancreatic cancer is greater than 93%. It is the fourth leading cause of cancer deaths in Hong Kong. Whipple (pancreaticoduodenectomy) operation is the only available curative treatment of pancreatic cancer. However, only 20% of patients are suitable for resection and the recurrence rate is high. In non-resectable cases and metastatic pancreatic cancer patients, the chemotherapeutic drug gemcitabine (GEM) remains the mainstream treatment. Nevertheless, GEM-based combination therapy exhibits profound chemoresistance with serious systemic toxicity. Gancao extract identified as anticancer agent In the search for alternative treatments for pancreatic cancer, a research team led by Dr Joshua Ko Ka-Shun, Associate Professor, Teaching and Research Division of the School of Chinese Medicine at HKBU, screened all the potential pancreatic cancer disease markers and the biological therapeutic activities of phytochemicals from the medicinal plant Glycyrrhiza glabra (licorice, or Gancao in Chinese) using network pharmacology. Network pharmacology is an emerging discipline which systematically catalogue the molecular interactions of a drug molecule in a living cell using complex computations, and has become an important tool in botanical drug discovery. Using this approach, the team identified ISL as a potential anticancer agent for the treatment of pancreatic cancer. With a series of cell experiments, the team demonstrated that ISL suppressed the growth and induced apoptosis (programmed cell death) of pancreatic cancer cells. In two human pancreatic cancer cell lines applied with 12.5 μM and 25 μM concentrations of ISL respectively, their cell survival rates were about 50% and 80% lower than the control cells with no ISL applied. The percentage of late stage apoptosis in the two cell lines was 11% and 13% respectively, compared to less than 5% in the control cells. Inhibits cancer progression with fewer side effects "ISL possesses a unique property of inhibiting pancreatic cancer progression through the blockade of autophagy, which is a natural process where the body's cells clean out damaged or unnecessary components. The blockade of late-stage autophagy in our experiments results in cancer cell death," said Dr Ko. The research team further employed a mice tumor model to investigate the efficacy of ISL in inhibiting pancreatic cancer cell growth in vivo. The mice were divided into three groups with GEM (GEM group), ISL (ISL group) and no treatment agent (control group) applied. The ISL group was further divided into two sub-groups treated with 30mg/kg and 60mg/kg of ISL. On the 21st day of the experiment, the tumor volumes of the control group and the GEM group were1000 mm3 and 400 mm3 respectively. The tumor volumes of the two ISL sub-groups treated with 30mg/kg and 60mg/kg of ISL were about 500 mm3 and 300 mm3 respectively. The results showed that ISL demonstrated treatment effects comparable to that of GEM. Meanwhile, compared with GEM, ISL showed fewer side effects in mice including neutropenia (drop in white blood cell count), anemia and body weight loss. Enhances effects of chemotherapies Current first-line chemotherapeutic drugs for pancreatic cancer, such as GEM and 5-fluorouracil (5-FU), are frequently associated with chemoresistance. It is because these drugs induce autophagy which favours the growth of cancer cells, and thus jeopardises their treatment effects. To explore ISL's potential in counteracting the chemoresistance of GEM and 5-FU, the research team set up experiments with pancreatic cancer cells treated with GEM or 5-FU alone, and GEM or 5-FU together with ISL. The growth inhibition rate of pancreatic cancer cells applied with GEM and ISL together is 18% higher than using GEM only, while the growth inhibition rate using 5-FU and ISL together is 30% higher than 5-FU only. The results showed that ISL can enhance the treatment effects of chemotherapeutic drugs by blocking autophagy, which is conducive to the death of cancer cells. "The findings in this study open a new avenue for developing ISL as a novel autophagy inhibitor in the treatment of pancreatic cancer. We hope to collaborate with other research partners to further evaluate the effectiveness and potential clinical application of ISL in treating pancreatic cancer," said Dr Ko. Hashtag: #pancreaticcancer #isoliquiritigeninThe issuer is solely responsible for the content of this announcement.

文章來源 : Media OutReach Limited 發表時間 : 瀏覽次數 : 2893 加入收藏 :
Acclime appoints Joshua Konechny as new Chief Digital Officer.

HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Acclime, Asia's leading tech-enabled professional services provider, is proud to announce the appointment of Joshua Konechny as the firm's Chief Digital Officer (CDO). This appointment underscores Acclime's dedication to remaining at the forefront of technological advancements in the corporate services sector. Joshua brings over 25 years of experience in delivering digital technologies to multiple business segments, including a strong corporate services portfolio. With his expertise, Acclime aims to further strengthen its foundation in tech enablement initiatives, fostering growth, efficiency, and seamless cross-cultural integration in its operations. Joshua expressed his enthusiasm for the CDO appointment: "I am honoured to lead the charge in driving tech enablement as a central pillar across the Acclime group. The organisation's commitment to leveraging innovation and technology to deliver exceptional corporate services is commendable. I look forward to collaborating closely with our talented teams throughout Asia to build on our successes and pioneer new frontiers in corporate services." To date, the Acclime group has successfully integrated over 40 companies, representing over 1,200 employees and 13,000 clients across 14 countries, each with its own unique cultural and regulatory challenges. The strong emphasis on technology-driven implementation has played a pivotal role in Acclime's seamless integration of these diverse entities, ensuring clients experience unified and cohesive service delivery across borders. Additionally, Acclime is actively invested in integrating new technologies, such as Artificial Intelligence (AI), into its service offerings. As Joshua noted, "The integration of AI technology is set to revolutionise corporate services, streamlining processes, and enhancing client outcomes. This AI integration will enable Acclime to provide even more robust, efficient, and personalised solutions to its clients, facilitating business growth and success in a rapidly evolving global landscape." Acclime's CEO, Martin Crawford, commented on Joshua's appointment: "We are delighted to appoint Joshua Konechny as our Chief Digital Officer. As a founding partner, he has provided a solid foundation of expertise since the inception of Acclime, and his appointment is a logical continuation of that excellent work. His expertise in harnessing technology for business transformation aligns perfectly with our vision of how professional services are performed and delivered to our clients. With our continued global expansion, Joshua's leadership will undoubtedly enhance our efforts to remain at the forefront of this innovation." Mr. Crawford explained another motivation behind the appointment, stating: "We see the extraordinary opportunities presented by digital transformation in all areas of business. We have invested heavily in technologies that enhance our internal efficiency, benefiting thousands of employees throughout the region. These technologies streamline and simplify the delivery of services to our clients. Constantly innovating our technology allows us to meet the complex corporate governance and digital security requirements around Asia. The CDO appointment will ensure proper oversight and industry-leading progress in both these areas." With Joshua Konechny as CDO, Acclime continues on an exciting path of bolstering its tech capabilities to embrace enhanced digitalization, AI integration, and a strengthened commitment to delivering exceptional corporate services. About Acclime   Acclime is a premier corporate and advisory services provider with operations in key Asia Pacific jurisdictions, including mainland China, Hong Kong, Malaysia, Thailand, Cambodia, Vietnam, Philippines, Indonesia, Singapore, India, Australia, and New Zealand. Global client service centres are provided in the UK, US, EU, and UAE.  The company's vision is to reinvent the corporate services sector with innovative solutions that help corporate and private clients advance their businesses and interests in Asia with a particular focus on difficult-to-navigate emerging markets. For enquiries, please visit www.acclime.com.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 808 加入收藏 :
Roche honored as one of the best companies to work in Vietnam for 2023

HO CHI MINH CITY, Vietnam, Aug. 7, 2023 /PRNewswire/ -- Roche Diagnostics Vietnam,  a leading healthcare company, was recently recognized as one of the best places to work in Vietnam for 2023. Best Places to Work is an international HR certification program providing employers in different countries the opportunity to learn more about the engagement and satisfaction of their employees, and honor those who deliver an outstanding work experience with the highest standards regarding working conditions. Employees ranked Roche Diagnostics Vietnam favorably in all the eight workplace factors of the certification (Leadership, HR Practices; Compensation; Benefits; Teamwork & relationships; Engagement; Workplace & Procedures and Corporate Social Responsibility). More than 94% of its employees find the organization a great employer, and highly value their leadership team; their relationship with colleagues; the environment within the workplace, and the flexibility, autonomy and life-work balance. Dr. Qadeer Raza, General Manager of Roche Diagnostics Vietnam, expressed his gratitude during the award ceremony, stating, "Roche - a Swiss multinational healthcare company, first introduced its innovative diagnostics solutions to Vietnam in 1954. Today, we are proud to have a strong presence across 63 provinces as a market leading in Diagnostics, working tirelessly to bring innovative diagnostic solutions to healthcare and patients throughout Vietnam. Our continuous growth and success can be attributed to our committed and passionate employees." Receiving the certification of the best place to work is a testament to Roche's unwavering dedication to its employees. He emphasized, "While we are honored to be recognized as one of the best places to work, our focus remains on empowering and providing the right environment to our employees for their growth and creating a result-driven culture in the interests of people and patients in Vietnam". Mr. Hoang Anh Huy, People & Culture Lead for Roche Diagnostics Vietnam added "To attract and retain talents, we leverage our position as a global pioneer in personalized healthcare and a world leader in in-vitro diagnostics to create personalized experiences and a rewarding environment for our employees to thrive and develop to their full potential. Specifically, we are trying to foster a culture of inclusion, mutual respect, and diversity. We encourage everyone to be open to discussing and considering new ideas, using their unique skills to bring value to patients and customers." Every year, the program partners with many organizations, across different industries, to help them measure, benchmark, improve their HR practices and have access to the tools and expertise they need to deliver effective and sustainable change in their organizations. For more information about the program, visit www.bestplacestoworkfor.org

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 716 加入收藏 :
Polish Running Icon Edyta Lewandowska Joins Amazfit as Brand Ambassador for UTMB 2023

CUPERTINO, Calif, Aug. 7, 2023 /PRNewswire/ -- Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, is thrilled to announce a collaboration with esteemed Polish runner, Edyta Lewandowska, as she takes on the ultimate challenge of the UTMB (Ultra-Trail du Mont-Blanc) this year. Lewandowska, a renowned champion in marathon, ultramarathon, and mountain running, will be wearing the Amazfit Cheetah Pro as she conquers the rugged terrain of the Mont-Blanc region. With an incredible track record and a personal best of 2:33:00 in the street marathon, Lewandowska has cemented her position as one of the most successful Polish runners. As the current world record holder in the Supermaratona dell' Etna, the world's most difficult uphill marathon, she has proven her unmatched determination and strength. Reflecting on her partnership with Amazfit, Lewandowska states, "I tame the predator. The cheetah is a very fast animal. Amazfit Cheetah Pro is as fast as me. I befriend him to serve me faithfully. My new friend leads me by the hand. We're just getting to know each other, and I already trust him." Lewandowska's remarkable achievements include winning the European Masters Vice-championship in mountain running twice and securing the World Masters Vice-championship in mountain running in 2022. Additionally, she achieved an impressive 2nd place in the Transvulcania Trail by UTMB in 2023. As a running coach and advocate for a healthy lifestyle, Lewandowska is not only dedicated to her own success but also to inspiring others to pursue their fitness goals. With over 27 years of professional sports experience, she has won 37 medals at the Polish Championships, including 9 gold medals, and has accumulated over 200,000 kilometers in her running journey. Amazfit invites running enthusiasts and fans to support Edyta Lewandowska as she takes on the challenging UTMB. Watch her conquer the mountains and witness the power of the Amazfit Cheetah Pro in action. For more updates on Edyta Lewandowska and the Amazfit Cheetah Pro, please visit https://www.amazfit.com/en/ and follow us on Facebook, Instagram, Twitter and YouTube. For more updates on Dean Karnazes' appearances, please join the Amazfit Sports Community. The Amazfit Cheetah Pro and Amazfit Cheetah (Round) are now available at Amazfit stores, Amazon and AliExpress. The Amazfit Cheetah (Square) will be available soon. The Amazfit Cheetah Pro is priced starting from $299.99 USD, while the Amazfit Cheetah (Round) is priced starting from $229.99 USD. Prices may vary depending on location. About Amazfit Amazfit, a leading global smart wearable brand focused on health and fitness, is part of Zepp Health (NYSE: ZEPP), a health technology company. Offering a wide selection of smartwatches and bands, Amazfit's brand essence is "Up Your Game", encouraging users to live their passions and express their active spirits freely. Amazfit is powered by Zepp Health's proprietary health management platform that delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award. Launched in 2015, Amazfit is today embraced by millions of users. Its products are available in more than 90 countries across the Americas, EMEA, and APAC regions. For more information about Amazfit, visit www.amazfit.com.  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 696 加入收藏 :
Pure Series Face Wash Bubble Cleanser helps skin health by making liquid soap with the natural cosmetics Pure Valley vegetable oil

Natural ingredient cosmetics that make your skin healthy and beautiful SEOUL, South Korea, Aug. 7, 2023 /PRNewswire/ -- The Ministry of SMEs and Startups selected 30 companies to participate in this year's Social Economy Enterprise Growth Support Project on the 18th, and Pure Valley, a cosmetics company established in 2015 with more than 25 years of R&D experience, was selected as one of the 30 companies. The Pure Valley product launched this time makes natural sanitizers and natural cosmetics that help skin health and improve skin problems rather than simple use and after use, and provides them to customers, according to the company. In addition, Pure Valley products include cosmetics made using natural materials and high-quality oils as the main base, and liquid soap-type cleansing cleansers, body wash, and shampoo without synthetic surfactants. Finally, the highly recommended feature of Pure Valley products is that the main ingredient used in natural detergents is liquid soap made using vegetable oil and that the characteristics and efficacy of oil are applied according to the purpose of each product. It is a natural cosmetic that is carefully made to protect skin health by using herbs that are effective for the human body according to the efficacy of the product, and it minimizes skin irritation by not using harmful preservatives and chemical additives. This item can be purchased here: https://www.amazon.com/dp/B0BHHKXJJK

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 456 加入收藏 :
JY Corporation launches pesticide-free certified enoki mushroom tea grown in Naju, Jeollanam-do

The Ministry of SMEs and Startups finally selected 30 companies to participate in this year's "Social Economy Enterprise Growth Intensive Support Project." SEOUL, South Korea, Aug. 7, 2023 /PRNewswire/ -- JY Corporation, a food company that distributes high-quality food at low prices to consumers, was finally selected as one of the 30 companies to participate in this year's "Social Economy Enterprise Growth Intensive Support Project" organized by the Ministry of SMEs and Startups. The company is loved by many consumers for selling high-quality foods as well as consumer health, including tea, Jeju Island black pork, and elephant garlic. The newly released enoki mushroom tea uses only pesticide-free enoki mushrooms and is produced and sold in amounts exceeding about 10 tons of enoki mushrooms. Enoki mushrooms, which are certified as pesticide-free, are manufactured using only pesticide-free enoki mushrooms grown at the Honam Mushroom Farming Association in Naju, Jeollanam-do, one of the largest producers of enoki mushrooms in Korea, and can be safely drunk. In addition, consumers' response is very good because the company uses its own far-infrared hot air drying and special roasting technology to maximize the nutrient content by drying only the moisture of the ingredients. JY Corporation is a company that is sold by a representative with nine years of business experience after direct inspection, and is preparing franchise services to expand the scope of sales and distribution. This item can be purchased here: https://www.amazon.com/dp/B09MD1YCNR

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 512 加入收藏 :
2025 年 1 月 7 日 (星期二) 農曆十二月初八日
首 頁 我的收藏 搜 尋 新聞發佈